Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma - Fase II MPM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002223-14-DK

Enrollment

Registered

2005-08-15

Start date

2005-08-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with malignant pleural mesothelioma who cannot be operated

Interventions

Trade Name: Carboplatin Product Name: carboplatin Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Carboplatin Other descriptive name: carboplatin Concentration unit: mg/ml milligram(s)/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: malignant pleural mesothelima ps 0-2 age>18 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: poor organ function

Design outcomes

Primary

Measure	Time frame
Main Objective: Efficacy Response;Secondary Objective: survival toxicity QOL;Primary end point(s): response rate	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026